Table 5.
Summary of risk ratio (RR) for main outcomes from collected studies by serogroup of RSV infections (note: 95% CI = 95% confidence interval; ARI = acute respiratory illness; LRTD = lower respiratory tract disease).
| Outcome | Studies | Total Samples | RSV A (/Total, %) |
RSV B (/Total, %) |
RR (95% CI) | Heterogeneity | ||
|---|---|---|---|---|---|---|---|---|
| I2 (95% CI) | τ2 (95% CI) | Q (p-Value) | ||||||
| 1st season, RSV A vs. RSV B | ||||||||
| ARI | [51,52,83] | 35,694 | 32 (0.09%) | 38 (0.11%) | 0.849 (0.529; 1.363) |
0.0% (0.0; 89.6) |
0.000 (0.000; 2.523) |
1.56 (0.458) |
| LRTD (3+ symptoms) |
[51,52,81] | 47,253 | 4 (0.01%) | 8 (0.2%) | 0.505 (0.150; 1.706) |
0.0% (0.0; 89.6) |
0.000 (0.000; 7.469) |
0.31 (0.856) |
| Follow-up studies, RSV A vs. RSV B | ||||||||
| LRTD (3+ symptoms) |
[48,51,52] | 33,130 | 13 (0.4%) | 26 (0.8%) | 0.499 (0.107; 2.327) |
0.0% (0.0; 89.6) |
1.167 (0.000; 59.266) |
6.29 (0.043) |